CVA Family Office’s Ultragenyx Pharmaceutical RARE Stock Holding History

CVA Family Office’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$701	Buy	+21	New	+$522	﹤0.01%	1687
2025 Q3	–	Sell	-14	Closed	-$509	–	1336
2025 Q2	$509	Buy	+14	New	+$505	﹤0.01%	1230
2022 Q4	–	Sell	-50	Closed	-$2K	–	996
2022 Q3	$2K	Hold	50	–	–	﹤0.01%	814
2022 Q2	$3K	Buy	+50	New	+$3.08K	﹤0.01%	806
2022 Q1	–	Sell	-10	Closed	-$1K	–	985
2021 Q4	$1K	Buy	+10	New	+$814	﹤0.01%	885

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

CVA Family Office's RARE Position: Q2 2026 in Review

CVA Family Office opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 21 shares worth $701. The stake represents ﹤0.01% of the portfolio and ranks #1687 among its holdings. This is a return to the name: CVA Family Office previously reported a position in RARE as recently as Q2 2025.

CVA Family Office first reported a position in RARE in Q4 2021 and has held it in 5 quarters since. The position peaked at $3K in Q2 2022. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

CVA Family Office held 21 shares of Ultragenyx Pharmaceutical worth $701 as of Q2 2026.
Ultragenyx Pharmaceutical was a new CVA Family Office position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1687 holding.
CVA Family Office first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 5 quarters since.
CVA Family Office's Ultragenyx Pharmaceutical position peaked at $3K in Q2 2022.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.